Bind appoints CEO
This article was originally published in Scrip
Bind Therapeutics, a clinical-stage nanomedicine platform company developing targeted therapeutics called Accurins, has named Andrew Hirsch acting president and CEO. Mr Hirsch was formerly Bind's chief operating officer and chief financial officer. He replaces Scott Minick, who will remain a member of the company's board of directors. Bind intends to announce a permanent CEO following an "expeditious evaluation of internal and external candidates."
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.